YD Bio Soars 129% on Nasdaq Debut Post-SPAC Merger, Secures $11.5M for Cancer & Ocular Therapies

Introduction

YD BIO LIMITED (NASDAQ: YDES) is a clinical-stage biopharmaceutical company that develops DNA methylation-based diagnostics for early cancer detection and exosome-based therapeutics for ocular and other diseases. The company also supplies investigational drugs and ancillary materials to global pharmaceutical firms for clinical trials.

Corporate Structure

Founded by Dr. Ethan Shen, who serves as Chairman and CEO, YD BIO LIMITED employs between 11 and 50 people. Dr. Shen has over three decades of experience in the pharmaceutical industry. The company maintains research collaborations and licensing agreements with partners such as 3D Global Biotech Inc. and EG BioMed Taiwan, and has established a U.S. laboratory dedicated to cancer-detection assays.

Biopharmaceutical by Melany @ tuinfosalud.com

Developments and News

On September 25, 2024, Breeze Holdings Acquisition Corp. announced a definitive agreement to merge with YD BIO LIMITED, with the intention of listing the combined entity in the U.S.
On August 15, 2025, the company disclosed in a Form 6-K that PIPE financing commitments totaled $13.2 million.
On August 20, 2025, YD BIO LIMITED filed Form 8-A12B with the SEC to register ordinary shares and warrants under Section 12(b).
On August 28, 2025, the SEC certified the company’s securities for listing (Form CERT).
Trading of YD BIO shares and warrants commenced on the Nasdaq Global Market on August 29, 2025, under the tickers YDES and YDESW.

Financial and Strategic Aspects

As of market open on August 29, 2025, YDES shares were priced at $12.16, reflecting a 129.43% increase from the prior close of $7.52, on a volume of 110,898 shares. The stock traded between $7.20 and $12.16 that day. Proceeds from the PIPE offering and trust release exceeded $11.5 million and are intended to fund operations, research and development, and commercialization of core products. YD BIO’s business model leverages licensing agreements—such as those for pancreatic and breast cancer methylation assays—and partnerships in ophthalmology to diversify revenue streams.

Market Position and Industry Context

YD BIO operates in the liquid-biopsy and exosome-therapy markets. Its patented methylation detection technology for pancreatic cancer addresses a demand for minimally invasive diagnostics. In ophthalmology, exosome-based treatments for conditions such as dry eye disease and glaucoma align with industry trends toward regenerative approaches. Listing on Nasdaq is expected to enhance visibility, facilitate future capital raises, and support collaboration with U.S. healthcare institutions.

tl;dr

YD BIO LIMITED closed its SPAC merger and began trading on Nasdaq on August 29, 2025, at $12.16 per share (up 129.43%). The company has raised over $11.5 million for research and development and commercialization. It plans to launch a breast cancer monitoring laboratory-developed test (LDT) and advance exosome-based ophthalmology trials scheduled for 2027.